Citco Integrates S3 Partners’ BLACKLIGHT Technology
30.5.2019 19:03:00 EEST | Business Wire | Press release
The Citco Group of Companies, (“Citco”), a leading provider of asset servicing solutions to the global alternative investment industry, today announced a product partnership with S3 Partners, a leading fintech innovator and data analytics firm, and the integration of its BLACKLIGHT Treasury Management solution.
S3 Partners’ real-time, independent financing data prices opaque borrow and loan markets and redefines short interest, crowding and previously stale indicators for which the industry has had no centralized source. BLACKLIGHT leverages these analytics along with leading technology for better outcomes in investment process, risk management, and counterparty relationships.
The agreement between Citco and S3 allows Citco clients to get the benefit of BLACKLIGHT’s Financing Trade Cost Analytics (FinTCA) tools to maximize trade, margin and collateral exposures and efficiencies. The platform will be rolled out via Citco’s Æxeo Treasury platform.
“Our focus at Citco has always been to provide our clients with the best technologies and services to make their lives easier. This is why we have decided to integrate S3’s market-standard BLACKLIGHT suite of data and technology,” said Albert Bauer, Managing Director at Citco Fund Services (USA) Inc. “Integrating BLACKLIGHT into our existing Citco framework enables us to provide S3’s efficient insights to best execution, cost of margin and working capital and to monitor liquidity alongside our new Æxeo Treasury platform. Our clients have asked for these nuanced analytics which we can now offer via BLACKLIGHT with single-sign-on access and virtually no operational friction.”
“We are thrilled that Citco has chosen to partner with us and recognizes the value of our broker-neutral solutions,” said Bob Sloan, Founder of S3 Partners. “The Citco-S3 alliance, along with our distribution via Bloomberg, Nasdaq and Reuters, expands the reach of our technology and data to every player type and client segment.”
About Citco Group of Companies
The Citco Group of Companies (Citco) is a leading provider of asset servicing solutions to the global alternative investment industry. With over $1 trillion in assets under administration and 6,500 staff deployed across 40 countries, Citco’s unique culture of innovation and client-driven solutions has provided Citco’s clients with a trusted partner for more than four decades. Having grown organically into one of the largest asset servicers in the industry, Citco’s Fund Services division offers a full suite of middle office and back office services including, treasury and loan handling, daily NAV calculations and investor services, corporate and legal services, regulatory and risk reporting as well as tax and financial reporting services. Investing heavily in innovation and technology whilst further developing its current suite of client friendly solutions, Citco will continue as a flagbearer for the asset servicing industry. For more information, go to www.Citco.com.
About S3 Partners
Founded in 2003, S3 Partners is a financial technology and data company. Clients use our technology and data for better outcomes in their investment process, risk management, counterparty relationships, and investor relations. Like any resource, the integrity and purity of data is defined by how it’s sourced, how and why it’s filtered, who can access it, and how it’s interpreted. Data is only potential until you find a way to refine it. Refining data potential into financial power is S3’s business. Our suite of tools arms you to not just access data but to wield it; cut through marketplace opacity and see with clarity where opportunity lies for your business, portfolio, and the entire market. S3’s comprehensive data integrity powers your market perception and business intelligence so you can act with agility, on your own terms. For more information about S3 Partners, please visit s3partners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005653/en/
Contact information
For Citco
New York
Hannah Beard | +1 646 274 1421
London
Aryna
Kastavetskaya | +44 20 3040 0871
citco@peregrinecommunications.com
For
S3 Partners
ASC Advisors
Steve Bruce / Taylor Ingraham
sbruce@ascadvisors.com
/ tingraham@ascadvisors.com
203-992-1230
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
